CLEC12B Decreases Melanoma Proliferation by Repressing Signal Transducer and Activator of Transcription 3

Area of Science:

• Dermatology
• Molecular Biology
• Cancer Research

Background:

• CLEC12B is a gene primarily expressed in skin melanocytes.
• Its specific role in melanoma development and progression remains largely uncharacterized.

Purpose of the Study:

• To investigate the function of CLEC12B in melanoma.
• To determine the correlation between CLEC12B expression levels and melanoma patient prognosis.

Main Methods:

• Transcriptomic analysis to identify CLEC12B expression patterns.
• In vitro studies assessing CLEC12B's effect on melanoma cell signaling pathways (STATs, p53).
• In vivo xenograft models in nude mice to evaluate tumor growth modulation.

Main Results:

• CLEC12B expression is significantly lower in melanoma tissues and metastases compared to normal melanocytes and benign lesions.
• Reduced CLEC12B levels correlate with poorer patient prognosis.
• CLEC12B recruits SHP2 phosphatase, inactivates STAT signaling, and upregulates p53/p21/p27, thereby inhibiting melanoma cell proliferation.
• Overexpression of CLEC12B reduces tumor growth in vivo, associated with decreased STAT3 phosphorylation and increased p53 levels.

Conclusions:

• CLEC12B acts as a tumor suppressor in melanoma.
• Its downregulation contributes to melanoma progression by promoting cell proliferation via STAT pathway activation and cell cycle dysregulation.